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Abstract
Aims In patients with heart failure with reduced ejection fraction (HFrEF) and iron deficiency, treatment with intravenous
iron has shown a clinical improvement regardless of anaemic status. Cardiac magnetic resonance (CMR) T2* sequence has
shown a potential utility for evaluating myocardial iron deficiency. We aimed to evaluate whether T2* sequence significantly
changes after ferric carboximaltose (FCM) administration, and if such changes correlate with changes in left ventricle ejection
fraction (LVEF).
Methods and results In this pilot study, we included eight patients with chronic symptomatic (New York Heart Associ-
ation II–III) HFrEF and iron deficiency. A CMR, including T2* analysis, was performed before and at a median of 43 days
(interquartile range = 35–48) after intravenous FCM administration. Pearson or Spearman correlation coefficient (r) was
used for bivariate contrast as appropriate. A partial correlation analysis was performed between ΔLVEF and ΔT2* while
controlling for anaemia status at baseline. Anaemia was present in half of patients. After FCM administration, T2*
decreased from a median of 39.5 (35.9–48) to 32ms (32–34.5), P = 0.012. Simultaneously, a borderline increase in median
of LVEF [40% (36–44.5) to 48.5% (38.5–53), P = 0.091] was registered. In a bivariate correlational analysis, ΔT2* was
highly correlated with ΔLVEF (r =0.747, P = 0.033). After controlling for anaemia at baseline, the association between
ΔT2* and ΔLVEF persisted [r(partial): 0.865, R2(partial): 0.748, P = 0.012]. A median regression analysis backed-up these
findings.
Conclusions In a small sample of patients with HFrEF and iron deficiency, myocardial iron repletion assessed by CMR was
associated to left ventricular remodelling. Further studies are warranted.
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Introduction
In patients with heart failure with reduced ejection fraction
(HFrEF), treatment with intravenous iron has shown to im-
prove symptoms, functional capacity, and quality of life re-
gardless of anaemic status.1,2 Experimental studies have
shown that iron deficiency (ID) led to structural and func-
tional abnormalities of the heart.3 In humans, a small report
showed a reduction in iron content of cardiomyocytes of pa-
tients with HFrEF compared with controls.4 More recently, in
a small clinical trial of patients with HFrEF, anaemia, and
chronic kidney disease, intravenous iron treatment was
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associated with improved myocardial function and cardiac
dimensions.5 Such findings led some authors to postulate
that part of the beneficial effect of iron treatment in HFrEF
is attributed to myocardial iron repletion.6 Nevertheless, no
study so far has evaluated the short-term effect of intrave-
nous iron therapy on myocardial iron content and its corre-
lation with simultaneous changes in left ventricular (LV)
function. Cardiac magnetic resonance (CMR) T2* sequence
has emerged as a reliable non-invasive technique for
assessing myocardial iron overload.7,8 Recently, this
technique has also shown a potential utility for evaluating
myocardial iron deficiency.9,10
Aims
We aimed to evaluate whether (i) T2* sequence significantly
changes after intravenous iron administration in patients
with ID with HFrEF, and (ii) if such changes correlate with si-
multaneous changes in CMR LV systolic function.
Methods
Study sample
In this observational pilot study, eight patients visited in the
heart failure (HF) unit of a third-level hospital from 29 Janu-
ary 2015 to 26 October 2015 were included. All of them
met the following inclusion criteria: (i) ID, defined as serum
ferritin <100μg/L or as ferritin 100–299μg/L with a transfer-
rin saturation <20%; (ii) New York Heart Association (NYHA)
functional class ≥II; (iii) clinical stability during the last
3months; and (iv) left ventricular ejection fraction (LVEF)
<50% assessed by transthoracic echocardiography within
the last 3months. In addition, the patients were excluded if
any of the following were documented: (i) severe to moder-
ate primary valve heart disease; (ii) acute coronary syndrome,
cardiac surgery, or revascularization within the previous
3months; and (iii) patients with pacemakers, intracardiac de-
fibrillators, and cardiac resynchronization devices. Informed
consent was obtained from every patient, and the study pro-
tocol conforms to the Declaration of Helsinki as reflected in a
priori approval by the institution’s human research
committee.
Protocol
Clinical, laboratory, electrocardiographic, distance walked in
6minutes (6MWT), Minnesota Living with Heart Failure Ques-
tionnaire (MLHFQ), and treatment characteristics were re-
corded in electronic forms. The patients enrolled underwent
a CMR within the first 7 days after ID diagnosis. Following
CMR, a single dose of 1000mg of ferric carboximaltose
(FCM) was administered to all patients. A second CMR, blood
laboratory, clinical assessment, 6MWT, and MLHFQ were
performed at a median of 43 days [interquartile range
(IQR) = 35–48] after FCM administration. Anaemia was de-
fined as haemoglobin (Hb) level <12 g/dL in women and
<13 g/dL in men.
CMR
All CMR studies (1.5 T unit, Magnetom Sonata, Siemens,
Erlangen, Germany) were performed by the same operator.
Steady-state free precession cine sequences at rest were
made, and the following were quantified: LV end-diastolic
and end-systolic volumes (LVEDV and LVESV) (mL/m2), LV
end-systolic diameter, LVEF determined by the Simpson
method (%), and LV mass (g/m2) determined by manually
outlining the endocardial borders in all short-axis cine slices.
The basic T2* pulse sequence was a single breath-hold,
multi-echo, gradient echo T2* sequence. In brief, a six-
element cardiac phased array coil and a chest saturation
band were used to image a single 10mm mid-ventricular
short axis slice at eight echo times from ~2 to ~18 with
2.0ms increments. Data were acquired every other cardiac
cycle.
For T2* analysis, a region of interest was chosen in the
mid-left ventricular septum. The mean signal intensities of re-
gion of interest were measured in the series of increasing
echo time images to give an exponential decay curve. The
monoexponential decay model and the nonlinear curve
fitting algorithm were used to fit the curve to obtain T2*
measurement. An example of T2* calculation is shown in
Figure S1.
Endpoints
Absolute changes in LVEF (ΔLVEF) (%) were selected as the
main endpoint. Secondary endpoints were absolute changes
in LV mass (ΔLVmass) (g/m2), LVEDV (ΔLVEDV) (mL/m2), and
LVESV (ΔLVESV) (mL/m2). Reverse remodelling was defined as
(i) LVEF increase≥ 15%, or (ii) LVEF increase ≥10%+ LV end-
systolic diameter reduction≥ 20%, or LVESV reduction≥ 40%.
Statistical analysis
Continuous variables were expressed in alignment with their
distribution, and discrete variables were expressed as percent-
ages. The median was always presented with IQR=25–75 per-
centiles as a measure of dispersion. The equality of each pair of
pre–post observations was tested either with paired t-test or
Wilcoxon matched-pair signed-rank test as appropriate.
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Pearson or Spearman correlation coefficient (r) was used for bi-
variate contrast as appropriate. A partial correlation analysis
was performed between ΔLVEF (dependent variable or Y) and
ΔT2* (independent variable or X) while controlling for anaemia
status at baseline (X2). Within the same framework, ΔLVmass,
ΔLVEDV, and ΔLVESV were contrasted with ΔT2*. The partial
correlation coefficient [r(partial)] reflects the degree of correla-
tion between X and Y after removing the effect of X2 on Y and
X2 on X. By the same token, the R2(partial) is interpreted as the
proportion of shared variance between Y and X controlling for
X2. To add robustness to the correlational analysis, we also
tested the relationship between ΔT2* and the median of
ΔLVEF by using quantile regression analysis (q= 0.5). In this lat-
ter analysis, anaemia at baseline and changes in haemoglobin
were used as covariates. A sensibility analysis assessing the re-
lationship between inverse of T2* (R2*) and changes in left
ventricular systolic function was also performed.
Results
The median (IQR) age was 81 (69–83) years; 62.5% patients
were women, 62.5% displayed NYHA III, and 87.5% were of
non-ischemic aetiology. Anaemia was present in half of pa-
tients. The median of LVEF, NT-proBNP, and estimated glo-
merular filtration rate were 40% (36–45), 3868 pg/mL
(1680–4841), and 38mL/min/1.73m2 (26–47), respectively.
Baseline characteristics are summarized in Table 1.
Clinical, laboratory, and CMR changes after
intravenous FCM
Clinical, laboratory, and CMR changes after intravenous FCM
are shown in Table 2. Briefly, NYHA class improved in 50% of
patients, and median 6MWT also showed a significant im-
provement. There was also an associated significant increase
in the median of ferritin [126μg/L (32 to 210) to 620μg/L
(535–814), P = 0.012] and transferrin saturation [17.7%
(15.3–19.8) to 29.6% (28.1–31.4), P = 0.012]. The increase in
Hb was borderline significant (12.2 ± 1.7mg/dL vs. 12.8
± 1.9mg/dL, P = 0.088). Regarding CMR parameters, T2*
decreased from a median of 39.5ms (35.9–48) to 32ms
(32–34.5), P = 0.012 (Figure 1a). Likewise, R2* significantly in-
creased after FCM (Figure S2). Simultaneously, a borderline
increase in the median of LVEF [40% (36–44.5) to 48.5%
(38.5–53) P = 0.091] and a decrease in the median of LVESV
[67mL/m2 (49–81) to 55mL/m2 (48–68), P = 0.093] were
registered (Figure S1). Reverse remodelling was observed in
four patients (50%). No significant changes were found for LV
end-diastolic volumes, LV mass, MLHFQ, or other biomarkers
(Figure S1 and Table S1).
Absolute changes in T2* and LVEF CMR
parameters
In a bivariate correlational analysis, ΔT2* was highly
correlated with ΔLVEF (r =0.747, P = 0.033). After
controlling for anaemia at baseline, the association between
ΔT2* and ΔLVEF persisted [r(partial) =0.865, R2(partial)
= 0.748, P = 0.012]. A median regression analysis backed-up
these findings. Indeed, per decrease in 1 unit of ΔT2*, there
Table 1. Baseline characteristics
Variable n=8
Demographics and medical history
Age, yearsb 81 (69-83)
Female, n (%) 5 (62.5)
Hypertension, n (%) 7 (87.5)
Diabetes Mellitus, n (%) 5 (62.5)
Dyslipidemia, n (%) 4 (50)
Active smoker, n (%) 2 (25)
Chronic renal disease, n (%) 5 (62.5)
Ischemic heart disease, n (%) 1 (12.5)
NYHA class III, n (%) 5 (62.5)
Atrial fibrillation, n (%) 4 (50%)
Vital signs and physical examination
Systolic blood pressure, mmHgb 122 ± 14
Diastolic blood pressure, mmHgb 61 ± 10
Heart rate, bpmb 75 ± 13
Peripheral edema, n (%) 4 (50)
Laboratory data
Hemoglobin, g/dL 12.2 ± 1.7
Anemiaa, n (%) 4 (50)
Ferritin, mg/dL 126 (32-210)
Transferrin saturation, % 17.7 (15.3-19.8)
Sodium, mEq/Lb 140 ± 2
Potassium, mg/dLb 4.5 ± 0.5
Urea, mg/dLb 106 ± 44
Creatinine, mg/dLb 1.79 ± 0.62
eGFR, mg/dL/1.73 m2 38 (26-47)
CA125, U/mL 20 (18-29.5)
NT-proBNP, pg/mL 3868 (1680-4841)
Cardiac magnetic resonance
LVEF, % 40 (36-45)
LVEDV, mL/m2 105.5 (90-129)
LVESV, mL/m2 67 (49-81)
LV mass, g/m2 92 (79.5-96.5)
Medical treatment
Diuretics, n (%) 8 (100)
Loop diuretics dose, mg/day 60 (40, 80)
Betablockers, n (%) 8 (100)
Aldosterone blockers, n (%) 8 (100)
ACEI, n (%) 5 (62.5)
ARB, n (%) 1 (12.5)
Statins, n (%) 6 (75)
NYHA: New York Heart Association; eGFR: estimated glomerular fil-
tration rate; CA125: antigen carbohydrate 125; NT-proBNP: amino-
terminal pro-brain natriuretic peptide; LVEF: left ventricle ejection
fraction; LVEDV: left ventricle end-diastolic volume; LVESV: left ven-
tricle end-systolic volume; LV: left ventricle; ACEI: angiotensin
converting enzyme inhibitors; ARB: angiotensin receptor blockers.
aAnemia was defined as hemoglobin lower than 13 mg/dL in men
and 12 mg/dL in women. Values for continuous variables are
expressed as median (interquartile range). Values for continuous
variables are expressed as median (interquartile range) unless
otherwise specified.
bVariable expressed as mean ± standard deviation.
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was an associated increase in the median of LVEF by a factor
of 0.81 (P = 0.007), having the sample adjusted by anaemia at
baseline (Figure 1b). The results did not significantly change
when absolute difference in pre–post Hb was used instead
as covariate (per decrease in 1 unit of ΔT2* and increase in
the median of LVEF of 0.88, P= 0.039), as shown in Figure 1c.
Likewise, the correlation analysis also showed a borderline
positive correlation between ΔLVEF and ΔR2* (r = 0.65;
R2 = 0.421; P = 0.082); after adjusting for anaemia at baseline,
such association became significant (r = 0.795; P = 0.0325)
Absolute changes in T2* and other CMR
parameters
ΔT2* was borderline correlated with ΔLVESV (r = 0.663,
P = 0.073), but it was not with ΔLVEDV (r = 0.052, P = 0.903)
nor ΔLVmass (r = 0.436, P = 0.280). After adjusting for
anaemia at baseline, the association between ΔT2* and
ΔLVESV became significant [r(partial) = 0.906, R2(partial)
= 0.821, P = 0.005]. Similarly, a quantile regression analysis
showed that the associations with ΔLVESV were significant
and in the same direction after adjusting either for anaemia
at baseline or ΔHb (β-coefficient = 0.65, P = 0.007 and β-
coefficient = 1.11, P = 0.048, respectively).
Discussion
This is the first study reporting a significant decrease in myo-
cardial T2* sequence after intravenous FCM administration.
In addition, we found a significant association between T2*
changes and short-term improvement in LVEF and LVESV in
a small group of elderly patients with chronic HFrEF of
Table 2. Changes in patients’ characteristics after FCM administration
Variable First assessment Second assessment P-value
Laboratory data
NT-proBNP, pg/mL 3868 (1680-4841) 3120.5 (1430-5788) 0.674
eGFR, mg/dL/1.73 m2 38 (26-47) 44 (29-51) 0.123
Hemoglobin, g/dLa 12.2 ± 1.7 12.8 ± 1.9 0.088
Ferritin, mg/dL 126 (32-210) 620 (535-814) 0.012
Transferrin saturation, % 17.65 (15.3-19.8) 29.6 (28.05-31.35) 0.012
Vital signs
SBP, mmHga 122 ± 14 130 ± 24 0.134
DBP, mmHga 61 ± 10 69 ± 18 0.136
Heart rate, bpm 72 (65.5-87) 68.5 (60-87) 0.205
Functional capacity
NYHA class≥III 5 (63%) 1 (13%) 0.039
6MWT 198 (160-236) 276 (169-342) 0.011
Quality of life
MLHFQ 55 (18-68) 27 (15-48) 0.293
FCM: ferric carboximaltose; NT-proBNP: amino-terminal pro-brain natriuretic peptide; eGFR: estimated glomerular filtration rate; SBP: sys-
tolic blood pressure; DBP: diastolic blood pressure; 6MWT; 6-minute walk test; MLHFQ: Minnesota Living with Heart Failure questionnaire
Values for continuous variables are expressed as median (interquartile range) unless otherwise specified.
aVariable expressed as mean ± standard deviation.
Figure 1 (a) Temporal changes in median of cardiac magnetic resonance T2* sequence after intravenous ferric carboximaltose administration. (b)
ΔLVEF and ΔT2*, adjusting for anaemia at baseline. (C) ΔLVEF and ΔT2* adjusting for changes in haemoglobin. CMR, cardiac magnetic resonance;
FCM, ferric carboximaltose; ΔLVEF, changes in left ventricular ejection fraction; ΔT2*, changes in T2*.
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predominant non-ischemic aetiology and ID. Interestingly,
the association persisted independent of Hb changes.
During the last decade, ID has become a well-recognized
therapeutic target in HFrEF.1,2,11 Two large randomized
placebo-controlled trials have shown that intravenous iron
administration was associated to improvement in symptoms,
functional capacity, quality of life, and reduction in HF hospi-
talizations.1,2 However, the pathophysiological mechanisms
underlying the effect of iron administration in HF remain
poorly understood, because clinical benefits have been ob-
served irrespective of anaemia status.1,2 Iron is a chemical
element that plays a central role in the oxidative metabolism
and muscle oxygen storage and transport.12
Despite the crucial role of iron in the physiology of cardio-
vascular system, this element remains understudied outside
of the erythropoietic system. Experimental studies have
shown that ID induced cardiac dysfunction13 and cardiac
hypertrophy, characterized by aberrant mitochondrial and
irregular sarcomere organization.14
Given previous evidence, it seems plausible to speculate
that ID may play a causative role in the pathophysiology of
HF beyond anaemia.4,6,11 Recently, Toblli et al., in a small ran-
domized trial in patients with HFrEF, ID, and chronic kidney
disease, showed that iron sucrose administration translated
into a significant 6-month improvement in LVEF by echocardi-
ography estimation (6.6 ± 3.8%).5 More recently, findings
from a cohort of 232 patients undergoing renal transplanta-
tion showed an increase of LVEF, particularly notorious in
those with systolic dysfunction pretransplantation.15 Because
these changes were strongly and positively related to
haemoglobin changes following transplantation, the authors
speculated a potential causal link between ID-anaemia and
HF progression in patients with chronic renal failure.15 Inter-
estingly, all patients included in the present study displayed
concomitant renal dysfunction. In summary, our results cor-
roborate the prior findings and add new evidence, suggesting
that myocardial iron repletion may explain, at least partially,
the beneficial effects of intravenous iron administration ob-
served in prior studies.
There are important limitations that need to be ac-
knowledged. First, this is small single centre observational
study using one magnetic resonance imaging system. How-
ever, we believe that eight patients in a pre–post testing
design provide enough statistical power to detect the ob-
tained effect size in T2* with an alpha of 0.05. Second,
T2* is a well-established sequence for quantification iron
overload, but the reliability for assessing ID remains more
debatable. Third, the magnitude of CMR changes may be
explained in part because of the inherent variability of the
technique. Further studies aiming to evaluate the reproduc-
ibility of T2* measurements are necessarily warranted.
Conclusions
In a small sample of patients with HFrEF, ID, and renal dys-
function, myocardial iron repletion, as assessed by CMR,
was associated to left ventricular remodelling. Further studies
are needed.
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Figure S1. Example of T2* measurement before and after
intravenous carboximaltose administration.
Figure S2. Cardiac magnetic resonance changes after intrave-
nous carboximaltose administration. R2*: Inverse of T2*LVEF:
left ventricle ejection fraction; LVEDV: left ventricle end-diastolic
volume; LVESV: left ventricle end-systolic volume; LVM: left
ventricular mass.
Table S1. Changes in patients’ characteristics after FCM
administration.
References
1. Anker SD, Comin Colet J, Filippatos G,
Willenheimer R, Dickstein K, Drexler H,
Lüscher TF, Bart B, Banasiak W,
Niegowska J, Kirwan BA, Mori C, von
Eisenhart RB, Pocock SJ, Poole-Wilson
PA, Ponikowski P, Trial Investigators
FAIR-HF. Ferric carboxymaltose in pa-
tients with heart failure and iron defi-
ciency. N Engl J Med 2009; 361:
2436–48.
2. Filippatos G, Farmakis D, Colet JC,
Dickstein K, Lüscher TF, Willenheimer
R, Parissis J, Gaudesius G, Mori C, von
Eisenhart RB, Greenlaw N, Ford I,
Ponikowski P, Anker SD. Intravenous fer-
ric carboxymaltose in iron-deficient
chronic heart failure patients with and
without anaemia: a subanalysis of the
FAIR-HF trial. Eur J Heart Fail 2013;
15: 1267–76.
3. Dong F, Zhang X, Culver B, ChewHGJr
KRO, Ren J. Dietary iron deficiency in-
duces ventricular dilation, mitochon-
drial ultrastructural aberrations and
cytochrome c release: involvement of ni-
tric oxide synthase and protein tyrosine
nitration. Clin Sci (London) 2005; 109:
277–286.
4. Maeder MT, Khammy O, Remedios C,
Kaye DM. Myocardial and systemic iron
depletion in heart failure implications
for anemia accompanying heart failure.
J Am Coll Cardiol 2011; 58: 474–80.
5. Toblli JE, Di Gennaro F, Rivas C.
Changes in echocardiographic parame-
ters in iron deficiency patients with
Reverse remodelling after intravenous iron administration 297
ESC Heart Failure 2016; 3: 293–298
DOI: 10.1002/ehf2.12101
heart failure and chronic kidney disease
treated with intravenous iron. Heart
Lung Circ 2015; 24: 686–95.
6. McMurray J, Ponikowski P. Heart failure
not enough pump iron? J Am Coll
Cardiol 2011; 58: 481–2.
7. Anderson LJ, Holden S, Davis B, Prescott
E, Charrier CC, Bunce NH, Firmin DN,
Wonke B, Porter J, Walker JM, Pennell
DJ. Cardiovascular T2-star (T2*) mag-
netic resonance for the early diagnosis
of myocardial iron overload. Eur Heart J
2001; 22: 2171–9.
8. Carpenter JP1, He T, Kirk P, Roughton
M, Anderson LJ, de Noronha SV,
Sheppard MN, Porter JB, Walker JM,
Wood JC, Galanello R, Forni G, Catani
G, Matta G, Fucharoen S, Fleming A,
House MJ, Black G, Firmin DN, St Pierre
TG, Pennell DJ. On T2* magnetic reso-
nance and cardiac iron. Circulation
2011; 123: 1519–28.
9. NagaoM,Matsuo Y, Kamitani T, Yonezawa
M, Yamasaki Y, Kawanami S, Abe K, Mukai
Y, Higo T, Yabuuchi H, Takemura A,
Yoshiura T, SunagawaK,HondaH.Quanti-
fication of myocardial iron deficiency in
nonischemic heart failure by cardiac T2*
magnetic resonance imaging. Am J Cardiol
2014; 113: 1024–30.
10. Nagao M, Baba S, Yonezawa M,
Yamasaki Y, Kamitani T, Isoda T,
Kawanami S, Maruoka Y, Kitamura Y,
Abe K, Higo T, Sunagawa K, Honda H.
Prediction of adverse cardiac events in
dilated cardiomyopathy using cardiac
T2* MRI and MIBG scintigraphy. Int J
Cardiovasc Imaging 2015; 31: 399–407.
11. Cohen-Solal A, Leclercq C, Deray G,
Lasocki S, Zambrowski JJ, Mebazaa A,
de Groote P, Damy T, Galinier M. Iron
deficiency: an emerging therapeutic tar-
get in heart failure. Heart 2014; 100:
1414–20.
12. Sawicki KT, Chang HC, Ardehali H. Role
of heme in cardiovascular physiology
and disease. J Am Heart Assoc 2015; 4:
e001138.
13. Goldstein D, Felzen B, Youdim M,
Lotan R, Binah O. Experimental iron
deficiency in rats: mechanical and
electrophysiological alterations in the
cardiac muscle. Clin Sci (Lond) 1996;
91: 233–9.
14. Dong F, Zhang X, Culver B, Chew HG Jr,
Kelley RO, Ren J. Dietary iron deficiency
induces ventricular dilation, mitochon-
drial ultrastructural aberrations and cy-
tochrome c release: involvement of
nitric oxide synthase and protein tyro-
sine nitration. Clin Sci (Lond) 2005;
109: 277–86.
15. Hawwa N, Shrestha K, Hammadah M,
Yeo PS, Fatica R, Tang WH. Reverse re-
modeling and prognosis following kid-
ney transplantation in contemporary
patients with cardiac dysfunction. J Am
Coll Cardiol 2015; 66: 1779–87.
298 J. Núñez et al.
ESC Heart Failure 2016; 3: 293–298
DOI: 10.1002/ehf2.12101
